People with chronic obstructive pulmonary disease (COPD) often need to use many different inhalers every day to help them breathe better. But now, there are newer inhalers that combine different ...
The future of AstraZeneca’s three-in-one inhaler Breztri, which was previously hit with a surprising FDA rejection, was hinging on the outcome of another phase 3 trial. And the results from that trial ...
Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrrolate) is a prescription inhaler that’s used for the long-term management of COPD in adults. Breztri ...
copd-pulmonology-xray-ca0416 The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of ...
With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
(Reuters) - AstraZeneca is eyeing the further growth of its respiratory treatments business as a three-drug inhaler was shown to prevent flare-ups and death in cases of smoker's lung. AstraZeneca said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results